Published in Circulation on June 01, 1995
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest (1998) 5.95
Circulating vascular growth factors and central hemodynamic load in the community. Hypertension (2012) 1.56
Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am J Pathol (1997) 1.50
Growth factor therapies for vascular injury and ischemia. Circulation (1995) 1.42
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol (1997) 1.37
Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. J Clin Invest (2006) 1.31
A nitric oxide releasing, self assembled peptide amphiphile matrix that mimics native endothelium for coating implantable cardiovascular devices. Biomaterials (2009) 1.15
Hyperhomocysteinemia inhibits post-injury reendothelialization in mice. Cardiovasc Res (2005) 1.12
Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol (2008) 1.07
VEGF polymorphisms and severity of atherosclerosis. J Med Genet (2005) 1.05
Surgical skin markers impair human saphenous vein graft smooth muscle and endothelial function. Am Surg (2011) 1.03
Endothelial cells overexpressing interleukin-8 receptors reduce inflammatory and neointimal responses to arterial injury. Circulation (2012) 0.95
VEGF blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ Res (2010) 0.94
Biocompatibility screening in cardiovascular implants. Z Kardiol (2005) 0.93
Biological behaviour of human umbilical artery smooth muscle cell grown on nickel-free and nickel-containing stainless steel for stent implantation. Sci Rep (2016) 0.91
Fibrinogen and fibrin based micro and nano scaffolds incorporated with drugs, proteins, cells and genes for therapeutic biomedical applications. Int J Nanomedicine (2013) 0.90
Enhanced human endothelial progenitor cell adhesion and differentiation by a bioinspired multifunctional nanomatrix. Tissue Eng Part C Methods (2012) 0.89
Paeonia lactiflora Extract Attenuating Cerebral Ischemia and Arterial Intimal Hyperplasia Is Mediated by Paeoniflorin via Modulation of VSMC Migration and Ras/MEK/ERK Signaling Pathway. Evid Based Complement Alternat Med (2013) 0.87
Contribution of recipient-derived cells in allograft neointima formation and the response to stent implantation. PLoS One (2008) 0.86
Ex vivo carbon monoxide delivery inhibits intimal hyperplasia in arterialized vein grafts. Cardiovasc Res (2010) 0.86
First in vitro and in vivo results of an anti-human CD133-antibody coated coronary stent in the porcine model. Clin Res Cardiol (2013) 0.86
Development of microporous self-expanding stent grafts for treating cerebral aneurysms: designing micropores to control intimal hyperplasia. J Artif Organs (2011) 0.83
Delivery of large biopharmaceuticals from cardiovascular stents: a review. Biomacromolecules (2007) 0.83
Compound ex vivo and in silico method for hemodynamic analysis of stented arteries. PLoS One (2013) 0.83
Molecular imaging of vascular endothelial growth factor receptors in graft arteriosclerosis. Arterioscler Thromb Vasc Biol (2012) 0.83
Vascular endothelial growth factor attenuates trauma-induced injury in rats. Br J Pharmacol (2000) 0.81
Vascular balloon injury and intraluminal administration in rat carotid artery. J Vis Exp (2014) 0.80
Isolation of endothelial cells and vascular smooth muscle cells from internal mammary artery tissue. Ochsner J (2007) 0.80
Vitreous mediators in retinal hypoxic diseases. Mediators Inflamm (2013) 0.79
Healing arterial ulcers: Endothelial lining regeneration upon vascular denudation injury. Vascul Pharmacol (2015) 0.77
Chemical activation and changes in surface morphology of poly(ε-caprolactone) modulate VEGF responsiveness of human endothelial cells. J Mater Sci Mater Med (2014) 0.77
Endovascular Gene Delivery from a Stent Platform: Gene- Eluting Stents. Angiol Open Access (2015) 0.77
Hypoxic regulation of VEGF, HIF-1(alpha) in coronary collaterals development. Korean J Intern Med (2005) 0.76
Study of novel coating strategy for coronary stents: simutaneous coating of VEGF and anti- CD34 antibody. Rev Bras Cir Cardiovasc (2015) 0.75
ATF-4 and vascular injury: integration of growth factor signaling and the cellular stress response. Circ Res (2008) 0.75
Nkx2-5 Is Expressed in Atherosclerotic Plaques and Attenuates Development of Atherosclerosis in Apolipoprotein E-Deficient Mice. J Am Heart Assoc (2016) 0.75
1H-pyrrole-2,5-dione-based small molecule-induced generation of mesenchymal stem cell-derived functional endothelial cells that facilitate rapid endothelialization after vascular injury. Stem Cell Res Ther (2015) 0.75
Endothelial repair in stented arteries is accelerated by inhibition of Rho-associated protein kinase. Cardiovasc Res (2016) 0.75
Endothelial KLF4: crippling vascular injury? J Am Heart Assoc (2014) 0.75
Inhibition of intimal hyperplasia via local delivery of vascular endothelial growth factor cDNA nanoparticles in a rabbit model of restenosis induced by abdominal aorta balloon injury. Exp Ther Med (2015) 0.75
Molecular Imaging of Angiogenesis and Vascular Remodeling in Cardiovascular Pathology. J Clin Med (2016) 0.75
Attenuated inhibition of adrenergic contraction by nitric oxide in injured guinea pig femoral artery. Heart Vessels (1997) 0.75
Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 30.27
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res (1999) 11.32
Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med (1999) 10.16
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med (1999) 9.18
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J (1999) 6.62
Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A (2000) 6.59
VEGF is required for growth and survival in neonatal mice. Development (1999) 6.16
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest (1998) 5.95
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A (1995) 5.92
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 5.04
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem (1992) 4.92
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem (1994) 4.41
The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell (1993) 4.33
Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet (1996) 4.32
Mouse model of angiogenesis. Am J Pathol (1998) 4.28
Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation (2001) 4.17
Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation (1998) 4.10
The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med (2001) 3.85
Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins (1977) 3.80
Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res (1998) 3.79
Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem (1998) 3.78
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther (1990) 3.55
Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest (1995) 3.52
Age-dependent impairment of angiogenesis. Circulation (1999) 3.47
Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature (2001) 3.42
Structural characterization and biological functions of fibroblast growth factor. Endocr Rev (1987) 3.40
Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res (2000) 3.39
Apoptosis in human atherosclerosis and restenosis. Circulation (1995) 3.30
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci U S A (1993) 3.01
Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem (1997) 2.95
Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol (1996) 2.95
Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation (1999) 2.92
Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem (2000) 2.87
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol (1999) 2.83
Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation (1996) 2.79
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A (2001) 2.77
The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem (1996) 2.75
Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med (1997) 2.73
Birth of a biome: insights into the assembly and maintenance of the Australian arid zone biota. Mol Ecol (2008) 2.73
Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet (2001) 2.70
Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol (1994) 2.66
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis (2010) 2.51
Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol (1999) 2.48
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun (1992) 2.47
Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development (2000) 2.43
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology (1996) 2.41
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst (2001) 2.27
Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: A key determinant of survival in diabetics after coronary balloon angioplasty. Circulation (2001) 2.26
Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun (1991) 2.25
Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation (1998) 2.25
Evidence implicating nonmuscle myosin in restenosis. Use of in situ hybridization to analyze human vascular lesions obtained by directional atherectomy. Circulation (1992) 2.20
Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem (1995) 2.20
HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest (2001) 2.20
Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest (1992) 2.19
Acute cardiac events temporally related to cocaine abuse. N Engl J Med (1986) 2.18
Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol (1992) 2.14
Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med (2000) 2.13
Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem (1998) 2.12
Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation (2000) 2.12